Opendata, web and dolomites

ENDOWAVE SIGNED

ENDObronchial microWAVE Ablation for the minimally invasive treatment of lung cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ENDOWAVE" data sheet

The following table provides information about the project.

Coordinator
ENDOWAVE LIMITED 

Organization address
address: 88 HARCOURT STREET
city: DUBLIN
postcode: D02D K18
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENDOWAVE LIMITED IE (DUBLIN) coordinator 50˙000.00

Map

 Project objective

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds. The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery due to co-morbidities.

ENDOWAVE have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive intervention. The patented technology uses a flexible catheter system, which can be navigated through the patient’s airway to deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. This SME Phase 1 Instrument funding will enable ENDOWAVE to complete detailed feasibility and business planning activities that will provide a platform for commercialisation of the technology. This will enable ENDOWAVE to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative market penetration forecasts. This project will lead to job generation within ENDOWAVE and the associated supply chain.

Ultimately, ENDOWAVE seeks to improve outcomes for lung cancer patients by providing a curative treatment, which can be delivered in a single minimally invasive procedure.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDOWAVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDOWAVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More